News and Announcements
GlaxoSmithKline Extends Service Agreement with MedAdvisor
- Published June 16, 2016 2:19PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
16th June 2016, ASX Announcement
Highlights
- GlaxoSmithKline (GSK) Australia extends its services agreement with MedAdvisor for a further 12 months.
- GSK will continue utilising MedAdvisor’s medication management platform to provide relevant information for patients prescribed three medicines within GSK Australia’s respiratory portfolio.
- Agreement will generate Patient Engagement Program (PEP), formerly knows as Medication Training and Adherence Campaigns (MTAC), revenue for MedAdvisor.
- Allows GKS Australia to leverage the MedAdvisor platform to support patients on the safe and effective use of these medicines.
MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company, is pleased to announce that the Australian arm of leading global pharmaceutical company, GlaxoSmithKline Australia Pty (GSK) has extended its services agreement with MedAdvisor for a further 12 months.
Under the agreement, GSK Australia will continue providing tailored messages to patients prescribed medicines with GSK Australia’s respiratory portfolio.
To view the full announcement, please click on the button below.
Company Updates
Following the Billions: Where the Hyperscalers are Betting on the Future
The roadmap for the next decade isn’t hidden in pitch decks—it’s written on the balance sheets of Microsoft, Amazon, and Google. Their collective investment is flowing into three key areas: GPU Chips, AI Factories, and Energy. This foundational buildout signals a $7–$20 trillion economic convergence, where the physical race for infrastructure and energy is paramount. The article also covers the powerful macro case for digital assets in this new era.
The Great Re-Allocation: Why AI is Forcing Smart Money From Software to Hard Science
Smart money is rapidly shifting its investment focus from commoditized software to hard science and deep tech, as AI dissolves traditional software moats. Discover the dual pressure on investors and the pivot to businesses with durable, real-world defensive barriers.
AI is The Cheapest, Highest-Leverage Investment You Will Ever Make
AI tools offer a 10x productivity increase for a minimal monthly cost, making them the highest-ROI investment in business today. However, this massive potential remains dormant. The real opportunity is not in owning the tools, but in having the strategic playbook to deploy them organization-wide and build a defensible competitive advantage.
Backed By Leading Investment Groups and Family Offices
